Progress in the risk assessment of hydroxychloroquine in frail elderly people

Hydroxychloroquine (HCQ) is an antimalarial drug also known to have anti‐inflammatory and antiviral effects. The antiviral action of HCQ has been a point of interest for many researchers because of its mechanism of action and the potential use it could have during the current COVID‐19 pandemic. Howe...

Descripción completa

Detalles Bibliográficos
Autores principales: Castagna, Alberto, Ruotolo, Giovanni, Manzo, Ciro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7954841/
https://www.ncbi.nlm.nih.gov/pubmed/33738381
http://dx.doi.org/10.1002/agm2.12140
Descripción
Sumario:Hydroxychloroquine (HCQ) is an antimalarial drug also known to have anti‐inflammatory and antiviral effects. The antiviral action of HCQ has been a point of interest for many researchers because of its mechanism of action and the potential use it could have during the current COVID‐19 pandemic. However, HCQ can cause QT interval prolongation. The current therapies used in COVID‐19 are changing as the pandemic develops. The aim of this article is to promote a validated risk score for QT prolongation in multidimensional assessment of COVID‐19 patients, especially in elderly and polypathological patients.

Ejemplares similares